Integra LifeSciences Selected for Healogics iSupply℠ Program
September 10 2018 - 4:01PM
Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading
global medical technology company, today announced it has been
selected as a primary provider for cellular-based tissue products
within Healogics® Inc. new iSupply program. This program is
exclusively available to Healogics’ hospital partners and is
focused on ensuring hospitals and patients receive the best value
from wound care products commonly used in Wound Care Centers® and
other sites of care.
Under Healogics new iSupply program, Integra will be a lead
provider for cellular-based tissue products - AmnioExcel® Amniotic
Allograft Membrane, AMNIOMATRIX® Amniotic Allograft Suspension,
PriMatrix® Dermal Repair Scaffold, PriMatrix® Ag Antimicrobial
Dermal Repair Scaffold for the treatment of acute and chronic
complex wounds, and Omnigraft® Dermal Regeneration Matrix for the
treatment of diabetic foot ulcers. Cellular-based tissue products
or skin substitutes are a group of FDA-regulated products that are
designed to repair, restore or replace dermal and epidermal tissue
architecture through different mechanisms of action. Integra’s
comprehensive suite of evidence-based product solutions are
designed to support the body’s natural restorative healing
process. In addition, Integra’s market leading total contact
casting system, TCC-EZ® for offloading and protection of wounds,
will also be available under the iSupply program.
“We are excited to be a primary provider of cellular-based
tissue products for the iSupply program,” said Robert T. Davis,
Jr., corporate vice president and president, Orthopedics and Tissue
Technologies. “Integra’s products were selected through a
rigorous analysis of published data and reviewed by Healogics’
value analysis committee of leading wound care clinicians.
This partnership with Healogics reinforces Integra’s
commitment to broader access to our advanced wound care products
and improving outcomes for patients with chronic wounds.”
“I have used Integra’s line of advanced wound care products and
believe they are a vital part of our iSupply Program,” said Dr.
Scott Covington, executive vice president of Provider Education at
Healogics. “Through this program, we are able to offer high
quality, cost-effective products to clinicians, who can confidently
use these products to care for their patients.”
About IntegraIntegra LifeSciences is a global
leader in regenerative technologies, neurosurgical and extremity
orthopedic solutions dedicated to limiting uncertainty for
clinicians, so they can focus on providing the best patient care.
Integra offers a comprehensive portfolio of high quality,
leadership brands that include AmnioExcel®, Bactiseal®, Cadence®,
Certas™, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®,
Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®,
SurgiMend®, TCC-EZ®, Titan™ and VersaTru™. For the latest
news and information about Integra and its brands, please visit
www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to,
statements concerning the products and services provided by
Integra. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from predicted or expected results. Among other things, the
willingness of surgical professionals to use Integra products may
affect the prospects for their use in surgical procedures. In
addition, the economic, competitive, governmental, technological
and other factors, identified under the heading "Risk Factors"
included in Item IA of Integra's Annual Report on Form 10-K for the
year ended December 31, 2017 and information contained in
subsequent filings with the Securities and Exchange Commission
could affect actual results.
About Healogics Headquartered in Jacksonville,
Fla., Healogics is the nation’s wound healing expert. Last year
over 330,000 patients received advanced wound care through a
nationwide network of 700 Wound Care Centers®. The Healogics team
is made up of nearly 3,000 employees, 4,000 affiliated physicians
and a Healogics Specialty Physician practice group of almost 300.
In addition to the company’s network of outpatient Centers,
Healogics partners with over 300 skilled nursing facilities to care
for patients with chronic wounds, and provides inpatient consults
at 85 partner hospitals. As the industry leader, Healogics has the
largest repository of chronic wound-specific patient data in the
country. The Healogics Wound Science Initiative, an effort launched
in 2017 to provide peer-reviewed research, recognizes the value and
relevance of big data and advanced analytics to drive continuous,
collaborative learning towards a better understanding of how to
efficiently utilize healthcare resources for patients with wounds.
For additional information, please visit Healogics.com.
CONTACT: Integra LifeSciences Holdings
Corporation
InvestorsSravan Emany (609)
936-2488sravan.emany@integralife.comMichael
Beaulieu609-750-2827michael.beaulieu@integralife.com
Media Laurene
Isip609-750-7984laurene.isip@integralife.com
Healogics Media ContactLeslie Niblock
904-524-2695leslie.niblock@healogics.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Mar 2024 to Apr 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Apr 2023 to Apr 2024